CD274 and prostate carcinoma: Although an increment of PD-L1 has already been shown for hypoxic breast and prostate cancer cells in vitro (51), the interplay of various factors of the tumor microenvironment or an additional impact of oncologic therapies may be necessary to promote this effect in HNSCC in vivo (23).